166 related articles for article (PubMed ID: 25141892)
21. Cost Evaluation of Irinotecan-Related Toxicities Associated With the UGT1A1*28 Patient Genotype.
Roncato R; Cecchin E; Montico M; De Mattia E; Giodini L; Buonadonna A; Solfrini V; Innocenti F; Toffoli G
Clin Pharmacol Ther; 2017 Jul; 102(1):123-130. PubMed ID: 28074472
[TBL] [Abstract][Full Text] [Related]
22. [Interest of UGT1A1 genotyping within digestive cancers treatment by irinotecan].
Boyer JC; Etienne-Grimaldi MC; Thomas F; Quaranta S; Picard N; Loriot MA; Poncet D; Gagnieu MC; Ged C; Broly F; Le Morvan V; Bouquié R; Gaub MP; Philibert L; Ghiringhelli F; Le Guellec C
Bull Cancer; 2014 Jun; 101(6):533-53. PubMed ID: 24977443
[TBL] [Abstract][Full Text] [Related]
23. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
Carlini LE; Meropol NJ; Bever J; Andria ML; Hill T; Gold P; Rogatko A; Wang H; Blanchard RL
Clin Cancer Res; 2005 Feb; 11(3):1226-36. PubMed ID: 15709193
[TBL] [Abstract][Full Text] [Related]
24. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan.
Cecchin E; Innocenti F; D'Andrea M; Corona G; De Mattia E; Biason P; Buonadonna A; Toffoli G
J Clin Oncol; 2009 May; 27(15):2457-65. PubMed ID: 19364970
[TBL] [Abstract][Full Text] [Related]
25. [Two cases of advanced colorectal cancer with UGT1A1*28 homozygosity treated by FOLFIRI].
Yokoyama S; Imamura Y; Hatano N; Fukuoka T; Usui H; Morita Y
Gan To Kagaku Ryoho; 2009 Jul; 36(7):1159-61. PubMed ID: 19620808
[TBL] [Abstract][Full Text] [Related]
26. High Resectability Rate of Initially Unresectable Colorectal Liver Metastases After UGT1A1-Adapted High-Dose Irinotecan Combined with LV5FU2 and Cetuximab: A Multicenter Phase II Study (ERBIFORT).
Phelip JM; Mineur L; De la Fouchardière C; Chatelut E; Quesada JL; Roblin X; Pezet D; Mendoza C; Buc E; Rivoire M
Ann Surg Oncol; 2016 Jul; 23(7):2161-6. PubMed ID: 26739304
[TBL] [Abstract][Full Text] [Related]
27. A phase I study of infusional 5-fluorouracil, leucovorin, oxaliplatin and irinotecan in Japanese patients with advanced colorectal cancer who harbor UGT1A1*1/*1,*1/*6 or *1/*28.
Sunakawa Y; Fujita K; Ichikawa W; Ishida H; Yamashita K; Araki K; Miwa K; Kawara K; Akiyama Y; Yamamoto W; Nagashima F; Saji S; Sasaki Y
Oncology; 2012; 82(4):242-8. PubMed ID: 22508373
[TBL] [Abstract][Full Text] [Related]
28. [Polymorphisms of UGT1A gene and irinotecan toxicity in Chinese colorectal cancer patients].
Wang Y; Xu JM; Shen L; Xu N; Wang JW; Jiao SC; Zhang JS; Song ST; Li J; Bao HY; Yang L; Li F
Zhonghua Zhong Liu Za Zhi; 2007 Dec; 29(12):913-6. PubMed ID: 18478930
[TBL] [Abstract][Full Text] [Related]
29. A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer.
Suenaga M; Mizunuma N; Matsusaka S; Shinozaki E; Ozaka M; Ogura M; Chin K; Yamaguchi T
Drug Des Devel Ther; 2015; 9():1653-62. PubMed ID: 25834402
[TBL] [Abstract][Full Text] [Related]
30. Prediction of response to combination chemotherapy with irinotecan in Greek patients with metastatic colorectal cancer.
Isaakidou A; Gazouli M; Aravantinos G; Pectasides D; Theodoropoulos GE
J Cancer Res Ther; 2016; 12(1):193-7. PubMed ID: 27072236
[TBL] [Abstract][Full Text] [Related]
31. Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy.
Massacesi C; Terrazzino S; Marcucci F; Rocchi MB; Lippe P; Bisonni R; Lombardo M; Pilone A; Mattioli R; Leon A
Cancer; 2006 Mar; 106(5):1007-16. PubMed ID: 16456808
[TBL] [Abstract][Full Text] [Related]
32. Predictive effects of bilirubin on response of colorectal cancer to irinotecan-based chemotherapy.
Yu QQ; Qiu H; Zhang MS; Hu GY; Liu B; Huang L; Liao X; Li QX; Li ZH; Yuan XL
World J Gastroenterol; 2016 Apr; 22(16):4250-8. PubMed ID: 27122675
[TBL] [Abstract][Full Text] [Related]
33. UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer.
Miyata Y; Touyama T; Kusumi T; Morita Y; Mizunuma N; Taniguchi F; Manabe M
Int J Clin Oncol; 2016 Aug; 21(4):696-703. PubMed ID: 26710796
[TBL] [Abstract][Full Text] [Related]
34. Prospective phase II trial of second-line FOLFIRI in patients with advanced colorectal cancer including analysis of UGT1A1 polymorphisms: FLIGHT 2 study.
Hirata K; Nagata N; Kato T; Okuyama Y; Andoh H; Takahashi K; Oba K; Sakamoto J; Hazama S; Mishima H
Anticancer Res; 2014 Jan; 34(1):195-201. PubMed ID: 24403462
[TBL] [Abstract][Full Text] [Related]
35. Phase I study of irinotecan and doxifluridine for metastatic colorectal cancer focusing on the UGT1A1*28 polymorphism.
Hazama S; Nagashima A; Kondo H; Yoshida S; Shimizu R; Araki A; Yoshino S; Okayama N; Hinoda Y; Oka M
Cancer Sci; 2010 Mar; 101(3):722-7. PubMed ID: 20028383
[TBL] [Abstract][Full Text] [Related]
36. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma.
Liu CY; Chen PM; Chiou TJ; Liu JH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Wang WS
Cancer; 2008 May; 112(9):1932-40. PubMed ID: 18300238
[TBL] [Abstract][Full Text] [Related]
37. The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens.
Lamas MJ; Duran G; Balboa E; Bernardez B; Candamio S; Vidal Y; Mosquera A; Giraldez JM; Lopez R; Carracedo A; Barros F
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1591-9. PubMed ID: 22535333
[TBL] [Abstract][Full Text] [Related]
38. Pretreatment selection of regimen according to genetic analysis improves the efficacy of chemotherapy in the first line treatment of metastatic colorectal cancer.
Kim DY; Paek TY; Oh SY; Kim YB; Lee JH; Lee MY; Choi ZS; Suh KW
J Surg Oncol; 2014 Mar; 109(3):250-4. PubMed ID: 24318863
[TBL] [Abstract][Full Text] [Related]
39. [Examination of UGT1A1 polymorphisms and irinotecan-induced neutropenia in patients with Colorectal cancer].
Teruya T; Nakachi A; Shimabukuro N; Toritsuka D; Azuma Y; Hanashiro K; Nishiki T; Ota M; Shimabuku M; Shiroma H
Gan To Kagaku Ryoho; 2015 May; 42(5):585-9. PubMed ID: 25981652
[TBL] [Abstract][Full Text] [Related]
40. Comet assay measures of DNA damage as biomarkers of irinotecan response in colorectal cancer in vitro and in vivo.
Wood JP; Smith AJ; Bowman KJ; Thomas AL; Jones GD
Cancer Med; 2015 Sep; 4(9):1309-21. PubMed ID: 26108357
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]